Yes, melatonin can be safely taken with Tagrisso (osimertinib)
There are no documented drug-drug interactions between melatonin and osimertinib, and concurrent use appears safe based on available evidence.
Drug Interaction Profile
The FDA-approved Tagrisso label specifically addresses drug interactions and identifies three key concerns 1:
- Strong CYP3A4 inducers (which decrease osimertinib exposure)
- BCRP or P-gp substrates (whose exposure osimertinib increases)
- QTc-prolonging medications (potential additive cardiac effects)
Melatonin does not fall into any of these categories. While melatonin has been shown to inhibit CYP1A2, CYP2C19, and CYP3A7 in vitro 2, osimertinib is primarily metabolized by CYP3A4 1. More importantly, osimertinib itself is not a significant CYP3A4 substrate in a clinically meaningful way—co-administration with simvastatin (a sensitive CYP3A4 substrate) increased simvastatin exposure by only 9%, which is clinically irrelevant 3.
Mechanistic Considerations
Osimertinib's pharmacology does not overlap with melatonin's metabolic pathways. Osimertinib inhibits P-gp and BCRP transporters 3, but melatonin is not a substrate of these transporters. The comprehensive drug interaction guidelines for NSCLC patients on small-molecule inhibitors do not list melatonin as a problematic co-medication with osimertinib 3.
Safety Profile of Melatonin
Melatonin has a generally favorable safety profile even in cancer populations:
- In older cancer patients (≥70 years), 2 mg daily melatonin supplementation for 90 days was safe, though it did not improve quality of life 4
- Most adverse effects are minor and short-lived (drowsiness, headache, mood changes) 5, 6
- Melatonin demonstrates pleiotropic anti-cancer effects including redox regulation, anti-inflammatory properties, and immune modulation that may theoretically complement cancer therapy 7
Clinical Caveats
While the combination appears safe, consider these practical points:
- Timing matters: Melatonin should be taken 1-2 hours before bedtime after a meal for optimal effect 4
- Dose considerations: Typical doses range from 1-6 mg depending on age and indication 8
- Monitor for sedation: If the patient is on other CNS-active medications (opioids, antidepressants), melatonin may contribute to additive sedation 2
- QTc monitoring: While melatonin itself doesn't prolong QTc, osimertinib can cause QTc prolongation (1.4% incidence) 9. If the patient is on multiple medications, periodic ECG monitoring is prudent per FDA guidance 1
Bottom line: Melatonin supplementation is appropriate for patients taking Tagrisso, with no dose adjustments needed for either medication.